The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward ...

In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...

Darzalex Faspro's supply and availability remain unaffected, and no new clinical studies were requested by the FDA.

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to ...

EMD Serono recently named Miguel Fernandez Alcalde as its new president. The new executive spoke with Pharmaceutical ...

The clinical hold is due to questions about BX004’s nebulizer device, temporarily pausing US enrollment in the cystic ...

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives ...